Patent intelligence · US
US 7205411
Aminopyridine derivatives as mGluR5 antagonists
Aminopyridine derivatives as mGluR5 antagonists
Patent details — US 7205411
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 17, 2007
- Expiration
- Apr 12, 2027
- Applicant
- Addex Pharmaceuticals S.A.
- Claims
- 5
- CPC classes
- A61P, A61P25/00, A61P25/04, A61P25/06
Quick answer
US 7205411 (Aminopyridine derivatives as mGluR5 antagonists) is held by Addex Pharmaceuticals S.A.. Status: granted. Granted Apr 17, 2007. Expires Apr 12, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Addex Pharmaceuticals S.A.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61P, A61P25/00, A61P25/04, A61P25/06, A61P25/14, A61P25/16
More from Addex Pharmaceuticals S.A.
Related pharmaceutical patents in our USPTO index.
-
US 11071729
1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
granted -
US 10071095
1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders
granted -
US 9938270
Mono-phosphate salt of 6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2A]pyridine (dipraglurant) and polymorphs thereof as negative allosteric modulator of MGLU5 receptor
granted -
US 9765091
Tetrahydropyrazolo [3,4-b] azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors
granted -
US 9737533
1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
granted -
US 9266834
1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
granted -
US 9226930
1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
granted -
US 9132122
1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
granted
Frequently asked questions
What is US patent 7205411?
US 7205411 (Aminopyridine derivatives as mGluR5 antagonists) is held by Addex Pharmaceuticals S.A.. Status: granted. Granted Apr 17, 2007. Expires Apr 12, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7205411?
Addex Pharmaceuticals S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.
When does US 7205411 expire?
Our index shows an expiration date of Apr 12, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.